elebsiran   Click here for help

GtoPdb Ligand ID: 14728

Synonyms: ALN-81890 | BRII-835 | VIR-2218
Compound class: Nucleic acid
Comment: Elebsiran (VIR-2218) is a N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) that is designed to target hepatitis B virus (HBV) RNA as a mechanism to combat chronic HBV infection [2]. The nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone.
References
1. Gane E, Lim YS, Kim JB, Jadhav V, Shen L, Bakardjiev AI, Huang SA, Cathcart AL, Lempp FA, Janas MM et al.. (2023)
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials.
J Hepatol, 79 (4): 924-932. [PMID:37290591]
2. Gupta SV, Fanget MC, MacLauchlin C, Clausen VA, Li J, Cloutier D, Shen L, Robbie GJ, Mogalian E. (2021)
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection.
Drugs R D, 21 (4): 455-465. [PMID:34741731]
3. Yuen MF, Lim YS, Yoon KT, Lim TH, Heo J, Tangkijvanich P, Tak WY, Thanawala V, Cloutier D, Mao S et al.. (2024)
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study.
Lancet Gastroenterol Hepatol, 9 (12): 1121-1132. [PMID:39389081]